SK hynix And 2 More Stocks Estimated To Be Trading Below Fair Value
In This Article:
As global markets grapple with concerns over economic slowdowns and fluctuating indices, investors are increasingly seeking opportunities in undervalued stocks. In such volatile times, identifying companies trading below their fair value can offer a strategic advantage for long-term growth.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Kaspi.kz (NasdaqGS:KSPI) | US$122.05 | US$243.53 | 49.9% |
| Ningxia Baofeng Energy Group (SHSE:600989) | CN￥14.40 | CN￥28.73 | 49.9% |
| Westgold Resources (ASX:WGX) | A$2.80 | A$5.60 | 50% |
| NSE (ENXTPA:ALNSE) | €29.30 | €58.25 | 49.7% |
| Litium (OM:LITI) | SEK8.22 | SEK16.43 | 50% |
| Ohara (TSE:5218) | ￥1304.00 | ￥2595.15 | 49.8% |
| Fluence Energy (NasdaqGS:FLNC) | US$21.09 | US$42.10 | 49.9% |
| Solstad Offshore (OB:SOFF) | NOK33.10 | NOK65.93 | 49.8% |
| Fine Foods & Pharmaceuticals N.T.M (BIT:FF) | €8.06 | €16.07 | 49.9% |
| Beijing Aosaikang Pharmaceutical (SZSE:002755) | CN￥10.93 | CN￥21.79 | 49.8% |
Underneath we present a selection of stocks filtered out by our screen.
SK hynix
Overview: SK hynix Inc., with a market cap of ?108.25 trillion, manufactures, distributes, and sells semiconductor products across Korea, China, the rest of Asia, the United States, and Europe.
Operations: The company generates ?49.22 billion from the manufacture and sale of semiconductor products across various regions, including Korea, China, the rest of Asia, the United States, and Europe.
Estimated Discount To Fair Value: 16.3%
SK hynix appears undervalued based on discounted cash flow analysis, trading at ?169,900, below the estimated fair value of ?203,101.42. The company recently reported a significant turnaround with a net income of KRW 4.12 trillion for Q2 2024 and introduced industry-leading GDDR7 graphics memory and PCB01 SSD products aimed at AI markets. Earnings are forecast to grow 49.22% annually over the next three years, outpacing the broader Korean market's growth rate.
BeiGene
Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments globally, with a market cap of $22.43 billion.
Operations: Pharmaceutical products generated $3.10 billion in revenue for the company.
Estimated Discount To Fair Value: 20.8%
BeiGene appears undervalued based on discounted cash flow analysis, trading at US$211.15, below the estimated fair value of US$266.51. Recent earnings show revenue growth to US$929.17 million for Q2 2024, up from US$595.26 million a year ago, and a reduced net loss of US$120.41 million compared to US$381.14 million previously. The company is expected to become profitable within three years and has made significant investments in expanding its U.S.-based manufacturing capabilities.